COMP <GO>
VKTX vs ACAD // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Viking Therapeutics Inc. (NASDAQ) VS. ACADIA Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: VKTX 3
— ACAD 5
■ METRIC PARITY
LAST: $26.83 (-1.65%) • MKT CAP: $3.48B
options-implied-move
—
LAST: $20.47 (-0.58%) • MKT CAP: $3.55B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VKTX VS. ACAD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VKTX | ACAD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 91.70% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 7.90% | -42.90 | ACAD | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 31.2x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.25% | 2.94% | -11.19 | ACAD | /fcf-yield <GO> |
| Operating Margin | — | 9.80% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 36.50% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 15.40% | 11.90% | +3.50 | VKTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 24.02 | 6.26 | +17.76 | VKTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ACAD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.3 | 45.7 | +2.60 | VKTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 35.0x | 8.5x | +26.50 | ACAD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.48B | $3.55B | -$69.0M | ACAD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VKTX REV | ACAD REV | VKTX GROSS % | ACAD GROSS % | VKTX FCF | ACAD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.10B | $1.07B | — | 91.7% | -$278.7M | $105.1M |
| FY 2024 | $422.6M | $957.8M | — | 91.5% | -$87.8M | $157.2M |
| FY 2023 | $282.3M | $726.4M | — | — | -$73.4M | $16.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VKTX // BETA 0.91
ACAD // BETA —